4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Aixia Zhang, Brian Cao. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA[J]. The Journal of Biomedical Research, 2012, 26(6): 467-473. DOI: 10.7555/JBR.26.20120057
Citation: Aixia Zhang, Brian Cao. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA[J]. The Journal of Biomedical Research, 2012, 26(6): 467-473. DOI: 10.7555/JBR.26.20120057

Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA

Funds: 

Science and Technology Foundation of Nanjing Medical University (No. 07NMUZ005)

More Information
  • Received Date: May 28, 2012
  • Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellu-lar carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent as-say (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recom-binant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blot-ting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).
  • Related Articles

    [1]Ya Xie, Zifeng Xu, Yumin Zhang, Yisheng Li, Pengyu Du, Chun Wang. First-episode psychiatric disorder risk from SARS-CoV-2 infection: A clinical analysis with Chinese psychiatric inpatients[J]. The Journal of Biomedical Research, 2025, 39(1): 50-60. DOI: 10.7555/JBR.38.20240005
    [2]Zheyue Wang, Qi Tang, Bende Liu, Wenqing Zhang, Yufeng Chen, Ningfei Ji, Yan Peng, Xiaohui Yang, Daixun Cui, Weiyu Kong, Xiaojun Tang, Tingting Yang, Mingshun Zhang, Xinxia Chang, Jin Zhu, Mao Huang, Zhenqing Feng. A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling[J]. The Journal of Biomedical Research, 2023, 37(3): 166-178. DOI: 10.7555/JBR.36.20220221
    [3]Jiao Chen, Can Zhao, Yingzi Huang, Hao Wang, Xiang Lu, Wei Zhao, Wei Gao. Malnutrition predicts poor outcomes in diabetic COVID-19 patients in Huangshi, Hubei[J]. The Journal of Biomedical Research, 2022, 36(1): 32-38. DOI: 10.7555/JBR.35.20210083
    [4]Liu Zhi, Wang Jianwei, Ge Yiyue, Xu Yuyu, Guo Mengchen, Mi Kai, Xu Rui, Pei Yang, Zhang Qiankun, Luan Xiaoting, Hu Zhibin, Chi Ying, Liu Xingyin. SARS-CoV-2 encoded microRNAs are involved in the process of virus infection and host immune response[J]. The Journal of Biomedical Research, 2021, 35(3): 216-227. DOI: 10.7555/JBR.35.20200154
    [5]Chen Wei, Hu Zhiliang, Yi Changhua, Chi Yun, Xiong Qingfang, Tan Chee Wah, Yi Yongxiang, Wang Lin-Fa. An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report[J]. The Journal of Biomedical Research, 2020, 34(6): 470-474. DOI: 10.7555/JBR.34.20200099
    [6]Yun Yangfang, Song Hengyi, Ji Yin, Huo Da, Han Feng, Li Fei, Jiang Nan. Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification[J]. The Journal of Biomedical Research, 2020, 34(6): 458-469. DOI: 10.7555/JBR.34.20200044
    [7]Gorzalski Andrew J., Hartley Paul, Laverdure Chris, Kerwin Heather, Tillett Richard, Verma Subhash, Rossetto Cyprian, Morzunov Sergey, Van Hooser Stephanie, Pandori Mark W.. Characteristics of viral specimens collected from asymptomatic and fatal cases of COVID-19[J]. The Journal of Biomedical Research, 2020, 34(6): 431-436. DOI: 10.7555/JBR.34.20200110
    [8]Mehta Neha, Qiao Renli. Medical management of COVID-19 clinic[J]. The Journal of Biomedical Research, 2020, 34(6): 416-421. DOI: 10.7555/JBR.34.20200118
    [9]Slonim Anthony D., See Helen, Slonim Sheila. Challenges confronting rural hospitals accentuated during COVID-19[J]. The Journal of Biomedical Research, 2020, 34(6): 397-409. DOI: 10.7555/JBR.34.20200112
    [10]Yang Wei. Editorial commentary on special issue of COVID-19 pandemic[J]. The Journal of Biomedical Research, 2020, 34(6): 395-396. DOI: 10.7555/JBR.34.20200701
  • Cited by

    Periodical cited type(3)

    1. Ranjbar M, Asadi M, Nourigorji M, et al. Development of a recombinant nucleocapsid protein-based ELISA for the detection of IgM and IgG antibodies to SARS-CoV-2. Biotechnol Appl Biochem, 2021. DOI:10.1002/bab.2308. Online ahead of print
    2. Castillo-Olivares J, Wells DA, Ferrari M, et al. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. Front Immunol, 2021, 12: 748291. DOI:10.3389/fimmu.2021.748291
    3. Qasem A, Shaw AM, Elkamel E, et al. Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations. Curr Issues Mol Biol, 2021, 43(2): 728-748. DOI:10.3390/cimb43020053

    Other cited types(0)

Catalog

    Article Metrics

    Article views (4330) PDF downloads (1348) Cited by(3)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return